Diligence memo · auto-generated · as of July 2, 2026
Matchpoint Therapeutics Inc.
Matchpoint Therapeutics Inc. looks fair against its niche peers and is dormant on financing cadence.
Businessfiled
Matchpoint Therapeutics Inc. operates in Pharmaceuticals, based in CAMBRIDGE.
Sub-sector tags: pharma.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Matchpoint Therapeutics Inc. has raised $42M in disclosed capital across 1 recorded round, aggregated from public filings. Its latest round is modeled as Series C (a $40M–$100M round).
Largest single filing: $42M on 2022-10-05.
Most recent recorded round closed around 2022-10-05.
Valuation (modeled)modeled
Provath models Matchpoint Therapeutics Inc. at approximately $672M (range $136M–$1.3B). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Fair. Modeled value is 1.17× the median modeled value of Series C Pharmaceuticals companies in 2022–2024 (30 peers) — value vs value, same stage and era. Within the normal band (117% of peer median) for its niche.
Financing rhythm & timingmixed
Last raise 3.7 yr ago; this sector typically re-raises about every 13 months.
Only one round on record and long silent — often defunct, acquired, or gone quiet.
Comparablesmixed
Capital scale ranks ahead of 79% of Pharmaceuticals peers (1613 compared).
Modeled value ranks above 84% of those peers.
Closest niche peers: Vigil Neuroscience, Inc., Leap Therapeutics, Inc., Alimera Sciences Inc, VYNE Therapeutics Inc., Lusaris Therapeutics, Inc..
Peoplefiled
4 named people on file across officers, directors and signatories.
Risks & flagsmixed
Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.